Adicet Bio Inc (ACET) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adicet Bio Inc (ACET) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.49 Million) by net assets ($140.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adicet Bio Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Adicet Bio Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adicet Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adicet Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lee Feed Mill Public Company Limited
BK:LEE
|
0.019x |
|
GrowGeneration Corp
NASDAQ:GRWG
|
-0.005x |
|
Betamek Bhd
KLSE:0263
|
0.023x |
|
Adyton Resources Corp
V:ADY
|
0.004x |
|
Kingstate Electronics
TWO:3206
|
0.095x |
|
Nordisk Bergteknik AB Series B
ST:NORB-B
|
-0.004x |
|
Aeye Inc
NASDAQ:LIDR
|
-0.093x |
|
Manba Finance Ltd
NSE:MANBA
|
-0.483x |
Annual Cash Flow Conversion Efficiency for Adicet Bio Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Adicet Bio Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Adicet Bio Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.21 Million | $-95.25 Million | -0.598x | -20.85% |
| 2024-12-31 | $186.61 Million | $-92.38 Million | -0.495x | +10.11% |
| 2023-12-31 | $170.18 Million | $-93.72 Million | -0.551x | -259.64% |
| 2022-12-31 | $292.34 Million | $-44.77 Million | -0.153x | +9.08% |
| 2021-12-31 | $303.13 Million | $-51.05 Million | -0.168x | +55.49% |
| 2020-12-31 | $109.83 Million | $-41.55 Million | -0.378x | -181.91% |
| 2019-12-31 | $-60.37 Million | $-27.88 Million | 0.462x | +364.74% |
| 2018-12-31 | $104.20 Million | $-18.18 Million | -0.174x | +24.96% |
| 2017-12-31 | $49.69 Million | $-11.55 Million | -0.232x | -948.40% |
| 2016-12-31 | $304.44 Million | $8.34 Million | 0.027x | -72.20% |
| 2015-12-31 | $254.21 Million | $25.06 Million | 0.099x | -9.63% |
| 2014-12-31 | $233.58 Million | $25.48 Million | 0.109x | -10.55% |
| 2013-12-31 | $194.64 Million | $23.73 Million | 0.122x | +54.37% |
| 2012-12-31 | $168.00 Million | $13.27 Million | 0.079x | -18.90% |
| 2011-12-31 | $144.15 Million | $14.04 Million | 0.097x | +178.13% |
| 2010-12-31 | $124.35 Million | $-15.50 Million | -0.125x | -169.42% |
| 2009-12-31 | $125.38 Million | $22.51 Million | 0.180x | +44.01% |
| 2008-12-31 | $123.67 Million | $15.42 Million | 0.125x | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more